2015/01/01 by Victor Fedorenko, Olga Genilloud, Liliya Horbal +4 · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Microbial Natural Products and Biosynthesis #Microbial Metabolism and Applications #Genomics and Phylogenetic Studies
paper · pdf · doi:10.1155/2015/591349
openalex publication_date 2015/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/27
Concern over the reports of antibiotic-resistant bacterial infections in hospitals and in the community has been publicized in the media, accompanied by comments on the risk that we may soon run out of antibiotics as a way to control infectious disease. Infections caused by Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Clostridium difficile, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and other Enterobacteriaceae species represent a major public health burden. Despite the pharmaceutical sector's lack of interest in the topic in the last decade, microbial natural products continue to represent one of the most interesting sources for discovering and developing novel antibacterials. Research in microbial natural product screening and development is currently benefiting from progress that has been made in other related fields (microbial ecology, analytical chemistry, genomics, molecular biology, and synthetic biology). In this paper, we review how novel and classical approaches can be integrated in the current processes for microbial product screening, fermentation, and strain improvement.